HCW Biologics Inc. (HCWB)
NASDAQ: HCWB · Real-Time Price · USD
0.593
-0.028 (-4.43%)
At close: Mar 9, 2026, 4:00 PM EDT
0.582
-0.011 (-1.82%)
After-hours: Mar 9, 2026, 7:52 PM EDT
HCW Biologics Revenue
HCW Biologics had revenue of $15.61K in the quarter ending September 30, 2025, a decrease of -96.34%. This brings the company's revenue in the last twelve months to $422.03K, down -87.93% year-over-year. In the year 2024, HCW Biologics had annual revenue of $2.57M, down -9.68%.
Revenue (ttm)
$422.03K
Revenue Growth
-87.93%
P/S Ratio
8.08
Revenue / Employee
$11,723
Employees
36
Market Cap
3.41M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionHCWB News
- 7 days ago - HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter - GlobeNewsWire
- 20 days ago - HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules - GlobeNewsWire
- 24 days ago - HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune - GlobeNewsWire
- 3 months ago - HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease - GlobeNewsWire
- 4 months ago - HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results - GlobeNewsWire
- 4 months ago - HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting - GlobeNewsWire
- 5 months ago - HCW Biologics to Participate in the 2025 Maxim Growth Summit - GlobeNewsWire
- 5 months ago - HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program - GlobeNewsWire